LifePolymer™ is the primary blood and tissue contacting surface of the TRIA™ heart valve. The materials used in the TRIA™ valve were qualified for use after extensive testing to ISO and other standards for long-term implants. A portfolio of tests is provided to assist in the risk management assessment of LifePolymer™ for potential applications beyond heart valves. Foldax® is actively licensing its LifePolymer™ portfolio for other applications.
The Foldax® team has more than 20 years of experience producing these types of polymer compositions and additional expertise is provided by our elite Scientific Advisory Board.
Foldax® has been issued multiple US and OUS patents and has a number of additional patent applications pending. The issued patents are related to composition of matter, synthetic method and a variety of applications. Foldax® completed an outright acquisition of the LifePolymer™ patent portfolio from CSIRO in 2023.
“The CSIRO research team developed LifePolymer™ to the specifications provided by Foldax. CSIRO has over three decades of R&D experience in designing polyurethanes for medical applications. This expert knowledge in chemical structure property relationships in polyurethanes helped the team to design LifePolymer™ , combining excellent mechanical properties and long-term biostability. The unique combination of chemical components results in a polyurethane with a three-phase morphology, high resistance to creep deformation, ease of fabricating into thin films by solvent casting, and excellent hemocompatibility.”
--Thilak Gunatillake, Ph.D.
